Literature DB >> 28139360

Course of psychotic symptoms, depression and global functioning in persons at clinical high risk of psychosis: Results of a longitudinal observation study over three years focusing on both converters and non-converters.

Michael P Hengartner1, Karsten Heekeren2, Diane Dvorsky2, Susanne Walitza3, Wulf Rössler4, Anastasia Theodoridou2.   

Abstract

The aim of this study was to test the validity of the CHR state by focusing on the course of psychosis spectrum symptoms, depression and global functioning in converters and non-converters. A total of 188 CHR-positive subjects (60.2% men) aged between 13 and 35years (mean=20.5) at study outset were assessed five times (t0-t4) over a total observation period of 36months. Conversion to manifest psychosis was defined according to ICD-10 criteria for schizophrenia (F20) or brief psychotic disorder (F23). Measures of positive and negative symptoms were assessed with the Structured Interview for Prodromal Syndromes (SIPS), depression with the Calgary Depression Scale (CDS), and global functioning with the Global Assessment of Functioning Scale (GAF). Converters scored higher over time on all SIPS scales apart from grandiosity (Cohen's d: 0.5-0.7; all p<0.001), higher on the CDS (d=0.43, p=0.001) and lower on the GAF (d=0.69, p<0.001) than did non-converters. Positive and negative symptoms as well as depression were most severe at study outset (t0) and then declined sharply following a linear function over the three-year observation period (t1-t4) across groups (all linear contrasts p<0.001). In conclusion, converters showed significantly more psychopathological symptoms and poorer functioning before crossing the diagnostic threshold for manifest psychosis. CHR-subjects who convert to manifest psychosis during follow-up appear to be recovering from illness rather than becoming ill. Major issues involve the poor discrimination of CHR state and psychosis as well as the dichotomous definition of both at-risk and disease states. Further examination in other CHR-samples is warranted.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high risk; Conversion; Diagnosis; Psychosis; Schizophrenia; Transition

Mesh:

Year:  2017        PMID: 28139360     DOI: 10.1016/j.schres.2017.01.040

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  8 in total

1.  Rethinking the Psychosis Threshold in Clinical High Risk.

Authors:  Andrea Raballo; Michele Poletti; William T Carpenter
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

2.  A Supervised Exercise Intervention for Youth at Risk for Psychosis: An Open-Label Pilot Study.

Authors:  Derek J Dean; Angela D Bryan; Raeana Newberry; Tina Gupta; Emily Carol; Vijay A Mittal
Journal:  J Clin Psychiatry       Date:  2017 Nov/Dec       Impact factor: 4.384

3.  Timing of menarche and abnormal hippocampal connectivity in youth at clinical-high risk for psychosis.

Authors:  Katherine S F Damme; Ivanka Ristanovic; Teresa Vargas; Vijay A Mittal
Journal:  Psychoneuroendocrinology       Date:  2020-04-30       Impact factor: 4.905

4.  External validation and extension of the NAPLS-2 and SIPS-RC personalized risk calculators in an independent clinical high-risk sample.

Authors:  K Juston Osborne; Vijay A Mittal
Journal:  Psychiatry Res       Date:  2019-06-21       Impact factor: 3.222

5.  Predictive validity of conversion from the clinical high risk syndrome to frank psychosis.

Authors:  Laura A Yoviene Sykes; Maria Ferrara; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Diana O Perkins; Daniel H Mathalon; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan; Kristen A Woodberry; Albert R Powers; Allison N Ponce; John D Cahill; Jessica M Pollard; Vinod H Srihari; Scott W Woods
Journal:  Schizophr Res       Date:  2019-12-19       Impact factor: 4.939

6.  Coping with Unusual ExperienceS for 12-18 year olds (CUES+): a transdiagnostic randomised controlled trial of the effectiveness of cognitive therapy in reducing distress associated with unusual experiences in adolescent mental health services: study protocol for a randomised controlled trial.

Authors:  Suzanne Jolley; Sophie Browning; Richard Corrigall; Kristin R Laurens; Colette Hirsch; Karen Bracegirdle; Kimberley Gin; Francesca Muccio; Catherine Stewart; Partha Banerjea; Elizabeth Kuipers; Philippa Garety; Majella Byrne; Juliana Onwumere; Evanthia Achilla; Paul McCrone; Richard Emsley
Journal:  Trials       Date:  2017-12-04       Impact factor: 2.279

7.  The latent structure of depressive symptoms across clinical high risk and chronic phases of psychotic illness.

Authors:  Teresa Vargas; Anthony O Ahmed; Gregory P Strauss; Cassandra M Brandes; Elaine F Walker; Robert W Buchanan; James M Gold; Vijay A Mittal
Journal:  Transl Psychiatry       Date:  2019-09-16       Impact factor: 6.222

8.  Borderline Personality Pathology in an At Risk Mental State Sample.

Authors:  Tobias Paust; Anastasia Theodoridou; Mario Müller; Christine Wyss; Caitriona Obermann; Wulf Rössler; Karsten Heekeren
Journal:  Front Psychiatry       Date:  2019-11-14       Impact factor: 4.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.